Últimas noticias sobre Mapath Capital (OTC:IVFZF) Bolsa

Mapath Capital Corp is currently seeking business opportunities.

MAPATH CAPITAL CORP by MAPATH CAPITAL CORP.

Mapath Capital Corp

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Sysco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYY#NYSE">SYY</a>)</h3>
<ul>
<li>Dividend Yield: 3.03%</li>
<li>Barclays analyst Jeffrey Bernstein maintained an Overweight rating and cut the price target from $87 to $77 on April 30, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Wells Fargo analyst Edward Kelly maintained an Overweight rating and lowered the price target from $87 to $80 on April 30, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Recent News: On April 29, Sysco reported worse-than-expected third-quarter earnings and revenue.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest SYY <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0501">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0501"><img loading="lazy" decoding="async" width="907" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01043211/image-6.png" alt="" class="wp-image-896412" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01043211/image-6.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01043211/image-6-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01043211/image-6-768x704.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>)</h3>
<ul>
<li>Dividend Yield: 3.15%</li>
<li>Stifel analyst Matthew Smith maintained a Buy rating and increased the price target from $168 to $186 on April 24, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Barclays analyst Gaurav Jain maintained an Overweight rating and boosted the price from $145 to $175 on Feb. 26, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On April 23, Philip Morris reported better-than-expected first-quarter financial results and raised its FY25 adjusted EPS guidance above estimates.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0501">latest PM news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0501"><img loading="lazy" decoding="async" width="907" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01043245/image-7.png" alt="" class="wp-image-896413" style="width:537px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01043245/image-7.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01043245/image-7-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01043245/image-7-768x701.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>)</h3>
<ul>
<li>Dividend Yield: 3.27%</li>
<li>Barclays analyst Lauren Lieberman maintained an Equal-Weight rating and cut the price target from $62 to $61 on March 27, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Morgan Stanley analyst Dara Mohsenian maintained an Equal-Weight rating and raised the price target from $60 to $63 on Feb. 14, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On April 14, Molson Coors Beverage's CEO Gavin Hattersley announced plans to retire by the end of 2025.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0501">latest TAP news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0501"><img loading="lazy" decoding="async" width="842" height="798" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01043317/image-2-2.png" alt="" class="wp-image-896414" style="width:508px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01043317/image-2-2.png 842w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01043317/image-2-2-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/01043317/image-2-2-768x728.png 768w" sizes="(max-width: 842px) 100vw, 842px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/media/25/04/45098332/jim-cramer-this-tech-stock-is-not-great-not-bad-alaska-air-can-still-go-lower">Jim Cramer: This Tech Stock Is &#8216;Not Great, Not Bad&#8217;, Alaska Air Can Still Go Lower</a> </li>
</ul>
Photo via Shutterstock

News

Dividends

Price Target

Markets

Analyst Ratings

Trading Ideas

Wall Street's Most Accurate Analysts Give Their Take On 3 Defensive Stocks With Over 3% Dividend Yields

Biotech

Health Care

General

PLSE

Pulse Biosciences Says Its Nanosecond PFA Technology Will Be Featured At The American Association For Thoracic Surgery 2025 Annual Meeting

Polaris Renewable Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PIF#TSX">PIF</a>) reported quarterly losses of $(0.47) per share. This is a 323.81 percent decrease over earnings of $0.21 per share from the same period last year. The company reported quarterly sales of $20.29 million which missed the analyst consensus estimate of $20.70 million by 2.00 percent. This is a 1.67 percent decrease over sales of $20.63 million the same period last year.

Earnings

Earnings Misses

TSX:PIF

Polaris Renewable Energy Q1 EPS $(0.47) Down From $0.21 YoY, Sales $20.29M Miss $20.70M Estimate

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) with a Buy and maintains $105 price target.

Reiteration

PRAX

HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $105 Price Target

AVXL

Anavex Completes Phase 2 Enrollment For ANAVEX3-71 In Schizophrenia Treatment Study, Top Line Data Expected In Second Half Of 2025

<a href="https://www.bloomberg.com/news/articles/2025-05-01/morgan-stanley-plans-to-offer-crypto-trading-to-e-trade-clients?taid=68134add8745050001de4533&amp;utm_campaign=trueanthem&amp;utm_medium=social&amp;utm_source=twitter&amp;sref=y3YMCJ4e" title="https://www.bloomberg.com/news/articles/2025-05-01/morgan-stanley-plans-to-offer-crypto-trading-to-e-trade-clients?taid=68134add8745050001de4533&amp;utm_campaign=trueanthem&amp;utm_medium=social&amp;utm_source=twitter&amp;sref=y3YMCJ4e">https://www.bloomberg.com/news/articles/2025-05-01/morgan-stanley-plans-to-offer-crypto-trading-to-e-trade-clients?taid=68134add8745050001de4533&amp;utm_campaign=trueanthem&amp;utm_medium=social&amp;utm_source=twitter&amp;sref=y3YMCJ4e</a>

"Morgan Stanley Is Working On A Plan to Add Cryptocurrency Trading To Its E-Trade Platform-Bloomberg

AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) affirms FY2025 Adj EPS guidance from $4.00-$4.50 to $4.00-$4.50 vs $3.88 analyst estimate..

Guidance

AGCO

AGCO Affirms FY2025 Adj EPS Guidance of $4.00-$4.50 vs $3.88 Est

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Vista Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VGZ#AMEX">VGZ</a>) with a Buy and maintains $2.75 price target.

HC Wainwright & Co. Reiterates Buy on Vista Gold, Maintains $2.75 Price Target

BSEM

BioStem to Highlight BioREtain Tech And Present Research At SAWC Spring, Co-Exhibits With Venture Medical

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4417146-1&amp;h=1786368412&amp;u=http%3A%2F%2Fwww.jacobs.com%2F&amp;a=Jacobs">Jacobs</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) was awarded a five-year contract by the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4417146-1&amp;h=3001264818&amp;u=https%3A%2F%2Fwww.westbasin.org%2F&amp;a=West+Basin+Municipal+Water+District">West Basin Municipal Water District</a> to provide <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4417146-1&amp;h=1044434393&amp;u=https%3A%2F%2Fwww.jacobs.com%2Fwhat-we-do%2Foperations-facility-management&amp;a=operations+and+maintenance+(O%26M)">operations and maintenance (O&amp;M)</a> services for the Edward C. Little Water Recycling Facility and its four other facilities, which comprise the largest water recycling operation of its kind in the U.S.
&nbsp;
The Edward C. Little Water Recycling Facility produces 40 million gallons per day and is the only treatment facility to exist that produces five different types of fit-for-purpose recycled water – water for irrigation, cooling towers, seawater intrusion barrier, groundwater recharge, and low and high pressure boiler feeds.

Jacobs Wins Five-Year Contract to Operate Edward C. Little Water Recycling Facility

Stephens &amp; Co. analyst Jim Salera reiterates Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) with a Overweight and maintains $60 price target.

CAKE

Stephens & Co. Reiterates Overweight on Cheesecake Factory, Maintains $60 Price Target

ARMP

Armata Secures $4.65M DoD Funding To Advance AP-SA02 Trial For Staph Bacteremia, Topline Data Expected Q2 2025

Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) lowers FY2025 sales outlook from $774.50 million-$788.00 million to $770.50 million-$785.00 million vs $778.51 million estimate.

THRY

Thryv Holdings Lowers FY2025 Sales Guidance from $774.50M-$788.00M to $770.50M-$785.00M vs $778.51M Est

Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) sees Q2 sales of $203.000 million-$206.000 million vs $203.04 million analyst estimate.

Thryv Holdings Sees Q2 Sales $203.000M-$206.000M vs $203.04M Est

Barrington Research analyst Gary Prestopino maintains Kadant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAI#NYSE">KAI</a>) with a Outperform and maintains $380 price target.

Barrington Research Maintains Outperform on Kadant, Maintains $380 Price Target

Earnings Beats

BCYC

Bicycle Therapeutics Q1 EPS $(0.88) Misses $(0.86) Estimate, Collaboration Revenue $9.98M Beat $7.78M Estimate

AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.09 by 355.56 percent. This is a 82.33 percent decrease over earnings of $2.32 per share from the same period last year. The company reported quarterly sales of $2.05 billion which met the analyst consensus estimate. This is a 30.01 percent decrease over sales of $2.93 billion the same period last year.

AGCO Q1 Adj. EPS $0.41 Beats $0.09 Estimate, Sales $2.05B Inline

PAPL

Pineapple Financial Launches Pineapple+ Broker Platform

Needham analyst Ryan MacDonald reiterates Udemy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) with a Buy and maintains $11 price target.

UDMY

Needham Reiterates Buy on Udemy, Maintains $11 Price Target

PRTC

PureTech Says It Will Present Results From Phase 2b ELEVATE IPF Trial Of Deupirfenidone (LYT-100) At American Thoracic Society International Conference, Regulatory And Strategic Planning Underway To Advance Deupirfenidone Into Phase 3 Development

Comments

Mapath Capital

Noticias

Últimas noticias sobre Mapath Capital (OTC:IVFZF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL